Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...

As a fully integrated waste-hauler, the firm leverages a vast network of collection routes and transfer stations, which bestow significant control over the waste stream, funneling waste from numerous ...